Significance of OCT3/4 and SOX2 antigens expression by leukemic blast cells in adult acute leukemia.

IF 2.1 Q3 ONCOLOGY

Journal of the Egyptian National Cancer Institute Pub Date : 2024-02-12 DOI:10.1186/s43046-024-00209-3

Salah Aref, Omnyia Khaled, Nadia El Menshawy, Emad Azmy, Mohamed Aref, Osama Salama, Nada Khaled

{"title":"Significance of OCT3/4 and SOX2 antigens expression by leukemic blast cells in adult acute leukemia.","authors":"Salah Aref, Omnyia Khaled, Nadia El Menshawy, Emad Azmy, Mohamed Aref, Osama Salama, Nada Khaled","doi":"10.1186/s43046-024-00209-3","DOIUrl":null,"url":null,"abstract":"Objective: This study aimed to address the prognostic impact of SOX2 and OCT3/4 expression on adult acute leukemia patients' outcomes.Methods: SOX2 and OCT3/4 expression by blast cells were evaluated by flow cytometry in 80 acute leukemia patients and 8 healthy controls.Results: Baseline SOX2 and OCT3/4 expression were significantly higher in both ALL (P = < 0.001, P = 0.005 respectively) and AML patients (P < 0.001, P = 0.003 respectively) as compared to control, and decline at complete remission (CR) and elevated again at relapse. High SOX2 and OCT3/4 levels were significantly correlated with the presence of adverse risk stratification parameters.Conclusion: Our findings indicated that both SOX2 and OCT3/4 could serve as biomarkers that could improve risk stratification of acute leukemia patients. Also, both SOX2 and OCT3/4 might be a therapeutic target, especially in resistant acute leukemia.","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"36 1","pages":"5"},"PeriodicalIF":2.1000,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Egyptian National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43046-024-00209-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aimed to address the prognostic impact of SOX2 and OCT3/4 expression on adult acute leukemia patients' outcomes.

Methods: SOX2 and OCT3/4 expression by blast cells were evaluated by flow cytometry in 80 acute leukemia patients and 8 healthy controls.

Results: Baseline SOX2 and OCT3/4 expression were significantly higher in both ALL (P = < 0.001, P = 0.005 respectively) and AML patients (P < 0.001, P = 0.003 respectively) as compared to control, and decline at complete remission (CR) and elevated again at relapse. High SOX2 and OCT3/4 levels were significantly correlated with the presence of adverse risk stratification parameters.

Conclusion: Our findings indicated that both SOX2 and OCT3/4 could serve as biomarkers that could improve risk stratification of acute leukemia patients. Also, both SOX2 and OCT3/4 might be a therapeutic target, especially in resistant acute leukemia.

查看原文本刊更多论文

成人急性白血病中白血病爆破细胞表达 OCT3/4 和 SOX2 抗原的意义。

研究目的本研究旨在探讨SOX2和OCT3/4的表达对成人急性白血病患者预后的影响：方法：通过流式细胞术评估了80名急性白血病患者和8名健康对照者的囊泡细胞中SOX2和OCT3/4的表达情况：结果：SOX2和OCT3/4的基线表达在两种急性白血病患者中均显著升高（P = 结论：SOX2和OCT3/4的基线表达在两种急性白血病患者中均显著升高：我们的研究结果表明，SOX2和OCT3/4可作为生物标记物，改善急性白血病患者的风险分层。此外，SOX2和OCT3/4都可能是治疗靶点，尤其是在耐药性急性白血病中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the Egyptian National Cancer Institute ONCOLOGY-

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

11 weeks

期刊介绍： As the official publication of the National Cancer Institute, Cairo University, the Journal of the Egyptian National Cancer Institute (JENCI) is an open access peer-reviewed journal that publishes on the latest innovations in oncology and thereby, providing academics and clinicians a leading research platform. JENCI welcomes submissions pertaining to all fields of basic, applied and clinical cancer research. Main topics of interest include: local and systemic anticancer therapy (with specific interest on applied cancer research from developing countries); experimental oncology; early cancer detection; randomized trials (including negatives ones); and key emerging fields of personalized medicine, such as molecular pathology, bioinformatics, and biotechnologies.